Vir Biotechnology, Inc. Stock News

CNBC's Meg Tirrell discusses VIR Biotechnology's antibody drug results and what it can do to aid the Covid pandemic with VIR Biotech CEO George Scangos.

The average of price targets set by Wall Street analysts indicates a potential upside of 107.4% in Vir Biotechnology, Inc. (VIR). While the effectiveness of this highly sought-after metric is question

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Gainers Peak Bio, Inc. (NASDAQ: PKBO) shares surged 105.8% to close at $7.82 on Friday. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Lade

– Data from multiple ongoing trials evaluating Vir’s two novel HBV therapies continue to demonstrate substantial reductions in hepatitis B surface antigen (HBsAg) with no new safety signals –

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Gainers Peak Bio, Inc. (NASDAQ: PKBO) jumped 115% to $8.17. Peak Bio reported closing of up to $100 million common stock purchase transaction with White Lion Capital. Ladenburg Thalmann initiated cov

Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding

U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session. Willdan Group, Inc. (NASDAQ: WLDN) surged 27.6% to

Vir Biotechnology obliterated expectations for its Covid drug in the third quarter, and Vir stock leaped above its 200-day line. The post Vir Obliterates Quarterly Sales Expectations As Covid Drug Del

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of 12,900% and 143.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the

SAN FRANCISCO, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that four abstracts highlighting new data from its hepatitis B virus (HBV) clinical program hav

Sales of GSK's vaccine segment, especially meningitis and influenza vaccines, are likely to have been an important contributor to third-quarter 2022 sales.

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter

SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the third quarter en